Alessandro Sanna

机构：Azienda Ospedaliero-Universitaria Careggi, University of Florence · ORCID：0000-0001-5663-4254

发表论文 167 篇 · 总被引 1350 次 · h-index 19

代表论文

• BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2024 · Blood · 被引 20)
• Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study (2024 · Cancers · 被引 20)
• Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents (2024 · Blood Cancer Journal · 被引 7)
• Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes (2025 · Leukemia · 被引 5)
• Management of infections for patient treated with ibrutinib in clinical practice (2024 · Frontiers in Oncology · 被引 5)
• Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience (2024 · HemaSphere · 被引 4)